2008 - Risk for cancer was still increased over 2 years after stopping hormone therapy

Cheung, Angela M.
August 2008
ACP Journal Club;8/19/2008, Vol. 149 Issue 2, p9
Academic Journal
The article focuses on a study regarding the health risks associated in postmenopausal women after stopping hormone therapy (HT) and presents the author's views on it. It describes the procedure of the study, which revealed that the risk of cancer increased in postmenopausal women, over 2 years after stopping estrogen and progestin therapy. The author suggests that postmenopausal women should weigh the benefits and risks of HT and use the lowest dose for the shortest possible duration.


Related Articles

  • Estrogen-Plus-Progestin Use and Mammographic Density in Postmenopausal Women: Women's Health Initiative Randomized Trial. McTiernan, Anne; Martin, Christopher F.; Peck, Jennifer D.; Aragaki, Aaron K.; Chlebowski, Rowan T.; Pisano, Etta D.; Wang, C. Y.; Brunner, Robert L.; Johnson, Karen C.; Manson, JoAnn E.; Lewis, Cora E.; Kotchen, Jane M.; Hulka, Barbara S. // JNCI: Journal of the National Cancer Institute;9/21/2005, Vol. 97 Issue 18, p1366 

    Background: Increased mammographic density reduces the sensitivity of screening mammography, is associated with increased breast cancer risk, and may be hormone related. We assessed the effect of estrogen-plus-progestin therapy on mammographic density. Methods: In a racially and ethnically...

  • Estrogen plus progestin increased risk for breast cancer in postmenopausal women.  // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p61 

    In postmenopausal women, estrogen plus progestin hormone therapy (HT) increases cases of total and invasive breast cancer and abnormal mammogram results. Women who have received HT had a greater incidence of total and invasive breast cancer than did women who received placebo. The increase in...

  • Menopause Management Selected Updates and Clinical Issues. Hudson, Tori // Townsend Letter;Feb/Mar2006, Issue 271/272, p146 

    The article offers information about menopause management. Postmenopausal women who discontinued estrogen-progestogen therapy are significantly more likely to experience recurrence of their hot flashes and nightsweats. Botanical and nutrient topical products are now existing to enhance female...

  • Ethynilestradiol 20 mcg plus Levonorgestrel 100 mcg: Clinical Pharmacology. Lello, Stefano; Cavani, Andrea // International Journal of Endocrinology;2014, p1 

    Estroprogestins (EPs) are combinations of estrogen and progestin with several actions on women's health. The different pharmacological composition of EPs is responsible for different clinical effects. One of the most used low-dose EP associations is ethinylestradiol 20mcg plus levonorgestrel...

  • Estrogen plus progestin increased risk for breast cancer in postmenopausal women: COMMENTARY. Thacker, Holly L. // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p61 

    The study by researchers R.T. Chlebowski and colleagues gives detailed information regarding breast cancer risk in late postmenopausal women using estrogen-plus-progestin hormone therapy (HT). No increased risk for breast cancer death was reported in HT users, and the diagnosis of metastatic...

  • Prempro affects breast cancer detection.  // Reactions Weekly;4/12/2008, Issue 1197, p3 

    The article discusses research being done on estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. It references a study by R. T. Chlebowski et al., which was published in the February 25, 2008 issue of "Archives of Internal Medicine." Results showed that...

  • Postmenopausal Hormone Therapy--the Final Word...Maybe.  // HealthFacts;Jun2003, Vol. 28 Issue 6, p6 

    Focuses on the Women's Health Initiative estrogen/progestin combination trial. Number of women who participated in the trial; Decline in cognitive functioning among women taking combination hormones; Risk of stroke.

  • THE TRUTH ABOUT HORMONES. Gorman, Christine; Park, Alice; Bower, Amanda; Cole, Wendy; DeQuine, Jeanne; McDowell, Jeanne // Time International (South Pacific Edition);7/22/2002, Issue 28, p44 

    Discusses research that suggests that hormone replacement therapy (HRT), often used to treat women approaching menopause, may not be as effective as previously thought. Former views that HRT could prevent the effects of aging and hold back heart disease, brittle bones, and dementia; Information...

  • Hormone trial for disease prevention stopped early. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);7/13/2002, Vol. 325 Issue 7355, p61 

    Reports that the Women's Health Initiative stopped a U.S. clinical trial to evaluate estrogen and progestogen in postmenopausal women. Purpose of the study to examine whether estrogen plus progestogen has a favourable or unfavourable effect on coronary heart disease and overall risks and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics